CA2491508A1 - Hcv fusion proteins with modified ns3 domains - Google Patents

Hcv fusion proteins with modified ns3 domains Download PDF

Info

Publication number
CA2491508A1
CA2491508A1 CA002491508A CA2491508A CA2491508A1 CA 2491508 A1 CA2491508 A1 CA 2491508A1 CA 002491508 A CA002491508 A CA 002491508A CA 2491508 A CA2491508 A CA 2491508A CA 2491508 A1 CA2491508 A1 CA 2491508A1
Authority
CA
Canada
Prior art keywords
polypeptide
ser
hcv
asp
modified
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002491508A
Other languages
English (en)
French (fr)
Inventor
Michael Houghton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2491508A1 publication Critical patent/CA2491508A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA002491508A 2002-07-02 2003-07-02 Hcv fusion proteins with modified ns3 domains Abandoned CA2491508A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US39369402P 2002-07-02 2002-07-02
US60/393,694 2002-07-02
US39451002P 2002-07-08 2002-07-08
US60/394,510 2002-07-08
PCT/US2003/020996 WO2004005473A2 (en) 2002-07-02 2003-07-02 Hcv fusion proteins with modified ns3 domains

Publications (1)

Publication Number Publication Date
CA2491508A1 true CA2491508A1 (en) 2004-01-15

Family

ID=30118384

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002491508A Abandoned CA2491508A1 (en) 2002-07-02 2003-07-02 Hcv fusion proteins with modified ns3 domains

Country Status (8)

Country Link
EP (1) EP1539809A4 (https=)
JP (2) JP2005532064A (https=)
CN (1) CN1678630A (https=)
AU (1) AU2003248818A1 (https=)
CA (1) CA2491508A1 (https=)
PL (1) PL374349A1 (https=)
RU (1) RU2005102484A (https=)
WO (1) WO2004005473A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7491808B2 (en) * 2000-06-15 2009-02-17 Novartis Vaccines And Diagnostics, Inc. HCV non-structural protein mutants and uses thereof
WO2004039950A2 (en) * 2002-10-25 2004-05-13 Chiron Corporation Activation of hcv-specific cells
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
NZ551319A (en) * 2004-05-17 2010-07-30 Novartis Vaccines & Diagnostic Truncated Hepatitis C virus NS5 domain and fusion proteins comprising same
ES2377978T3 (es) 2004-08-27 2012-04-03 Novartis Vaccines And Diagnostics, Inc. Mutantes de proteínas no estructurales de VHC y usos de los mismos
CN102614510A (zh) * 2004-10-18 2012-08-01 全球免疫股份有限公司 基于酵母的对慢性丙型肝炎感染的治疗
AU2011254055B2 (en) * 2004-10-18 2012-12-20 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
CA2618429A1 (en) * 2005-05-25 2007-03-22 Tripep Ab A hepatitis c virus non-structural ns3/4a fusion gene
KR20080056301A (ko) * 2005-10-13 2008-06-20 바이렉스 메디칼 코포레이션 면역 반응을 유도시키기 위한, Ｃ형 간염 바이러스폴리펩티드 및 Ｆｃ 단편을 함유하는 키메라 항원
GB0524408D0 (en) * 2005-11-30 2006-01-11 Glaxosmithkline Biolog Sa Vaccines
CA2646539A1 (en) 2006-03-23 2007-09-27 Novartis Ag Imidazoquinoxaline compounds as immunomodulators
WO2008024518A2 (en) * 2006-08-25 2008-02-28 Novartis Ag Hcv fusion polypeptides
JP2012503011A (ja) 2008-09-19 2012-02-02 グローブイミューン，インコーポレイテッド 慢性ｃ型肝炎ウイルス感染の免疫療法
US9321847B2 (en) 2010-09-20 2016-04-26 Ramot At Tel Aviv University Ltd. Activatable toxin complexes comprising a cleavable inhibitory peptide
WO2016160046A1 (en) * 2015-03-27 2016-10-06 Ortho-Clinical Diagnostics, Inc. Hcv ns4a/modified ns3 polypeptides and uses thereof
CN106749672B (zh) * 2016-11-18 2020-06-30 江西农业大学 一种丙型肝炎病毒融合抗原蛋白及其应用
CN111153963B (zh) * 2020-01-19 2021-08-10 华南理工大学 抗炎五肽及其提取分离方法和在改善记忆中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0992580B1 (en) * 1993-11-04 2005-03-09 Innogenetics N.V. Immunodominant human T-cell epitopes of Hepatitis C virus
CA2390082C (en) * 1999-11-24 2010-06-29 Chiron Corporation Novel hcv non-structural polypeptide
WO2001090812A1 (en) * 2000-05-23 2001-11-29 Massachusetts Institute Of Technology Ultraviolet fluoride nonlinear devices

Also Published As

Publication number Publication date
JP2005532064A (ja) 2005-10-27
WO2004005473A2 (en) 2004-01-15
PL374349A1 (en) 2005-10-17
WO2004005473A3 (en) 2004-04-01
EP1539809A4 (en) 2006-03-08
EP1539809A2 (en) 2005-06-15
AU2003248818A1 (en) 2004-01-23
JP2006265267A (ja) 2006-10-05
CN1678630A (zh) 2005-10-05
RU2005102484A (ru) 2006-01-20

Similar Documents

Publication Publication Date Title
US6562346B1 (en) Activation of HCV-specific T cells
CA2491508A1 (en) Hcv fusion proteins with modified ns3 domains
US20100291134A1 (en) Truncated hepatitis c virus ns5 domain and fusion proteins comprising same
KR20020065537A (ko) 신규한 ｈｃｖ 비구조 폴리펩티드
US7439058B2 (en) HBV/HCV virus-like particle
US6986892B1 (en) Immunogenic Hepatitis C virus non-structural polypeptides
EP1233783B9 (en) Hbv/hcv virus-like particle
US20050074465A1 (en) HCV fusion proteins with modified NS3 domains
US8216590B2 (en) HCV fusion polypeptides
CA2505611A1 (en) Activation of hcv-specific cells
EP1535628B1 (en) Hbv/hcv virus-like particle

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead